• synchronizing manufacturing readiness with expedited clinical timelines to ensure CMC never becomes the bottleneck for breakthrough small molecule therapies
• Leading high-impact HA interactions and CMC dossier strategies (M2/M3) to secure concurrent approvals across diverse global markets and regulatory jurisdictions
• Implementing proactive risk assessments and mitigation strategies to maintain compliance and supply continuity throughout the entire product life cycle
• Adapting technical operations to align with emerging ICH standards and regional CMC requirements, fostering “First-Pass” success in complex regulatory environments